WO2024254543A3 - Recombinant ancestral variant asparaginases and uses in managing cancer - Google Patents

Recombinant ancestral variant asparaginases and uses in managing cancer Download PDF

Info

Publication number
WO2024254543A3
WO2024254543A3 PCT/US2024/033129 US2024033129W WO2024254543A3 WO 2024254543 A3 WO2024254543 A3 WO 2024254543A3 US 2024033129 W US2024033129 W US 2024033129W WO 2024254543 A3 WO2024254543 A3 WO 2024254543A3
Authority
WO
WIPO (PCT)
Prior art keywords
asparaginases
recombinant
ancestral
ancestral variant
variant
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
PCT/US2024/033129
Other languages
French (fr)
Other versions
WO2024254543A2 (en
Inventor
Sunil RAIKAR
Christopher Doering
H. Trent SPENCER
Kristopher Knight
Harrison Brown
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Emory University
Childrens Healthcare of Atlanta Inc
Original Assignee
Emory University
Childrens Healthcare of Atlanta Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Emory University, Childrens Healthcare of Atlanta Inc filed Critical Emory University
Publication of WO2024254543A2 publication Critical patent/WO2024254543A2/en
Publication of WO2024254543A3 publication Critical patent/WO2024254543A3/en
Anticipated expiration legal-status Critical
Ceased legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
    • C12N9/14—Hydrolases (3)
    • C12N9/78—Hydrolases (3) acting on carbon to nitrogen bonds other than peptide bonds (3.5)
    • C12N9/80—Hydrolases (3) acting on carbon to nitrogen bonds other than peptide bonds (3.5) acting on amide bonds in linear amides (3.5.1)
    • C12N9/82—Asparaginase (3.5.1.1)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/43—Enzymes; Proenzymes; Derivatives thereof
    • A61K38/46—Hydrolases (3)
    • A61K38/50—Hydrolases (3) acting on carbon-nitrogen bonds, other than peptide bonds (3.5), e.g. asparaginase
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Y—ENZYMES
    • C12Y305/00—Hydrolases acting on carbon-nitrogen bonds, other than peptide bonds (3.5)
    • C12Y305/01—Hydrolases acting on carbon-nitrogen bonds, other than peptide bonds (3.5) in linear amides (3.5.1)
    • C12Y305/01001—Asparaginase (3.5.1.1)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/19—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles lyophilised, i.e. freeze-dried, solutions or dispersions
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Genetics & Genomics (AREA)
  • Zoology (AREA)
  • Wood Science & Technology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Biochemistry (AREA)
  • Epidemiology (AREA)
  • General Engineering & Computer Science (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Immunology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Molecular Biology (AREA)
  • Biomedical Technology (AREA)
  • Biotechnology (AREA)
  • Microbiology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Enzymes And Modification Thereof (AREA)

Abstract

Disclosed herein are recombinant asparaginases with ancestral variant sequences for uses as therapeutics. In certain embodiments, it is contemplated that the ancestral variant asparaginases have reduced immunogenicity thereby preventing or reducing the risk of host inactivation and/or anaphylaxis. In certain embodiments, this disclosure relates to treating diseases associated with asparagine dependence comprising administering an effective amount of an ancestral variant asparaginase or conjugate disclosed herein to a subject in need thereof.
PCT/US2024/033129 2023-06-09 2024-06-07 Recombinant ancestral variant asparaginases and uses in managing cancer Ceased WO2024254543A2 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US202363472192P 2023-06-09 2023-06-09
US63/472,192 2023-06-09

Publications (2)

Publication Number Publication Date
WO2024254543A2 WO2024254543A2 (en) 2024-12-12
WO2024254543A3 true WO2024254543A3 (en) 2025-04-24

Family

ID=93796467

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/US2024/033129 Ceased WO2024254543A2 (en) 2023-06-09 2024-06-07 Recombinant ancestral variant asparaginases and uses in managing cancer

Country Status (1)

Country Link
WO (1) WO2024254543A2 (en)

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1321519A1 (en) * 1996-06-07 2003-06-25 Kabushiki Kaisha Hayashibara Seibutsu Kagaku Kenkyujo Polypeptide having L-asparaginase activity

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1321519A1 (en) * 1996-06-07 2003-06-25 Kabushiki Kaisha Hayashibara Seibutsu Kagaku Kenkyujo Polypeptide having L-asparaginase activity

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
DATABASE UniProt 2 October 2024 (2024-10-02), "asparaginase {ECO:0000256|ARBA:ARBA00012920}", XP093307683, Database accession no. F6QHN0 *

Also Published As

Publication number Publication date
WO2024254543A2 (en) 2024-12-12

Similar Documents

Publication Publication Date Title
Kovacs et al. Guselkumab in the treatment of severe hidradenitis suppurativa
WO2005102307A3 (en) Beneficial effects of increasing local blood flow
WO2004046309A3 (en) Methods for inhibiting viral replication in vivo
WO2006098603A3 (en) Composition comprising isoorientin for suppressing histamine
WO2008049058A3 (en) Cln2 treatment of alzheimer's disease
US9011845B2 (en) Methods for treatment of inflammatory and infectious viral diseases
WO2024254543A3 (en) Recombinant ancestral variant asparaginases and uses in managing cancer
Akhavizadegan Electrocautery resection, shaving with a scalpel, and podophyllin: a combination therapy for giant condyloma acuminatum
Saini et al. A prospective randomized open label comparative study of efficacy and safety of intralesional measles, mumps, rubella vaccine versus 100% trichloroacetic acid application in the treatment of common warts
WO2024233365A3 (en) Uricase variants and methods of use thereof
US6147086A (en) Method employing imiquimod cream for treatment of topical sarcoidosis on equine
JP2022545253A5 (en)
MX2023001881A (en) Ribitol treatment.
WO2023081801A3 (en) Methods of treating sickle cell disease with voxelotor
EP1296554A4 (en) Prevention and treatment of mycoplasma-associated diseases
Edwards Managing wound pain in patients with burns using soft silicone dressings.
WO2023049534A3 (en) Subcutaneously administered foslevodopa/foscarbidopa treatments for advanced parkinson's disease
Gregersen et al. Therapy-resistant pretibial myxedema addressed with intralesional hyaluronidase
BR0112100A (en) Method of treatment of peripheral vascular diseases, peripheral neuropathies and autonomic neuropathies
WO2014003850A2 (en) Methods for treatment of ocular diseases
WO2002076393A3 (en) Antiagionecic, antitumor, chemopreventative agents
Mascarenhas et al. Efeito da terapia combinada no tratamento do queloide auricular
Neagu et al. Bromelain-based enzymatic debridement in hand burns–an easier way to manage a difficult patient: case report
WO2002002050A3 (en) Prevention and treatment of mycoplasma-associated diseases
MX2024000806A (en) Compositions and methods for preventing and/or treating disease associated with il-23 expression.

Legal Events

Date Code Title Description
121 Ep: the epo has been informed by wipo that ep was designated in this application

Ref document number: 24820189

Country of ref document: EP

Kind code of ref document: A2

NENP Non-entry into the national phase

Ref country code: DE